FeesSafety
Pluang+

Scancell's phase III melanoma vaccine trial set to start patient enrolment in Dec 2026.

Market News
20 Nov 2026, 02:14 WIB
Proactive Investors
View Source
Bullish
Scancell's phase III melanoma vaccine trial set to start patient enrolment in Dec 2026.

Scancell Holdings is on track to begin enrolling patients for its phase III melanoma vaccine trial in December 2026. The company's lead vaccine, inzitagene plasmivec, showed promising results with 87% overall survival at 24 months in a phase II study when combined with immunotherapy. The vaccine has also received a special FDA designation that could accelerate approval. Additionally, Scancell's second vaccine, Modi-1, showed encouraging tumor response in kidney cancer patients. The company plans to complete a merger and Nasdaq listing by early 2027, funded by a $39.1 million private placement contingent on the merger's completion.

Scancell's melanoma vaccine trial progress is the subject, with Pluang's health sector showing 20 of 150 US stocks rising and 130 falling as of Nov 20, 2026 04:02 WIB. Among notable movers, BrightSpring Health Services Inc. (BTSG) traded at USD 64.02 with a 6.32% decline and a typical hold time of 13 days, Hims and Hers Health Inc (HIMS) at USD 16.04 with an 82% sell order activity and 24 days hold, and UnitedHealth Group Inc (UNH) at USD 329.27 with a 67% buy order activity and 99 days hold.

More News

S&P 500's four-week drop after record high signals potential long-term gains, not a bear market.

S&P 500's four-week drop after record high signals potential long-term gains, not a bear market.

The S&P 500 recently experienced a four-week losing streak following a record high, dropping about 8% from its peak. Historically, such declines have often been healthy pullbacks rather than signs of a bear market, with the index showing gains six an...

Market News
Bullish
1 hour ago
Universal Technical Institute's revenue rises but profit falls, shares drop nearly 9%.

Universal Technical Institute's revenue rises but profit falls, shares drop nearly 9%.

Universal Technical Institute (UTI) reported a 6% increase in fourth-quarter revenue to $235.9 million, driven by a rise in full-time students. However, net income fell nearly 4% to just over $18 million, missing analyst earnings per share estimates....

Company Fundamentals
Bearish
1 hour ago
Michael Burry warns investors on risks in CoreWeave, Nebius, Nvidia, and chip stocks amid falling prices.

Michael Burry warns investors on risks in CoreWeave, Nebius, Nvidia, and chip stocks amid falling prices.

Investor Michael Burry highlighted risks in CoreWeave, Nebius, Nvidia, and semiconductor stocks, noting significant price drops due to rising borrowing costs and potential long-term challenges for Nvidia's competitive edge. CoreWeave and Nebius have ...

Market News
Bearish
1 hour ago
AMD's AI data center revenue nearly doubles, positioning it to challenge Nvidia's dominance.

AMD's AI data center revenue nearly doubles, positioning it to challenge Nvidia's dominance.

AMD is gaining ground on Nvidia in the AI chip market, with its data center revenue nearly doubling year over year in Q3 and overall revenue up 45%. Nvidia faces leadership uncertainty after former CEO Jensen Huang's departure, creating an opportunit...

Market News
Bullish
1 hour ago
Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App